Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA

Osteoarthritis Clinical Trial

Official title:

Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04589611
• Other study ID #: 201911366
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: July 20, 2022
• Est. completion date: December 1, 2023

Study information

• Verified date: March 2024
• Source: University of Iowa
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a small-scale proof-of concept clinical trial of amobarbital as a treatment to prevent post-traumatic osteoarthritis in fractured ankle joints. The study is a double blind, prospective, randomized, placebo-controlled, stepwise trial. Amobarbital will be delivered to ankle joints in solution with hyaluronic acid (HA) as a vehicle. Amobarbital/HA injections (active dose) will be compared to HA alone (placebo dose). Our primary goal is to confirm safety, but we will also assess whether treatment improves chondrocyte viability and decreases synovial inflammation. The intervention that will be utilized has proven to be effective using vitro and in vivo models. The study team will assess safety and begin to evaluate efficacy of amobarbital/Gel-One in patients having sustained tibial pilon fractures. The study team will use advanced imaging-based methods we have developed to characterize how joints subjected to varying levels of fracture severity and residual elevated contact stress respond in treated and control groups.

Description:

This is a small-scale proof-of concept clinical trial of amobarbital as a treatment to prevent post-traumatic osteoarthritis in fractured ankle joints. The study is a double blind, prospective, randomized, placebo-controlled, stepwise trial. Amobarbital will be delivered to ankle joints in solution with hyaluronic acid (HA) as a vehicle. Amobarbital/HA injections (active dose) will be compared to HA alone (placebo dose). Our primary goal is to confirm safety, but we will also assess whether treatment improves chondrocyte viability and decreases synovial inflammation. The intervention that will be utilized has proven to be effective using vitro and in vivo models. The study team will assess safety and begin to evaluate efficacy of amobarbital/Gel-One in patients having sustained tibial pilon fractures. The study team will use advanced imaging-based methods we have developed to characterize how joints subjected to varying levels of fracture severity and residual elevated contact stress respond in treated and control groups. Phase I:6 subjects will be treated with a single dose open label, and safety measures will be assessed. Phase II: Once initial safety is confirmed, 20 amobarbital:10 control subjects will be treated with the single dose at the initial operation. Assuming continued safety, an additional 20 amobarbital:10 control subjects will be treated with two doses and evaluated. The second dose of 2.5 mM amobarbital will be administered during the second operation. Subjects will participate in the following procedures: SOC surgical intervention Randomization to Amobarbital/Gel-One arm or control arm X-rays CT scans Blood and urine Questionnaires

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: December 1, 2023
• Est. primary completion date: December 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Age 18-60 years
• Acute closed or type 1 open ankle fractures (classified as OTA/AO 43 B 1-3 and 43 C 1- 3 or classified as 42 B and C fractures with 25% talar displacement and one of the following; syndesmosis injury or medial malleolar fracture at or above the shoulder) (Marsh et al., 2007)) without operative ipsilateral extremity trauma
• Posterior malleolar and supination adduction rotational fractures that have an articular fracture line across the articular surface of the distal tibia. Posterior malleolar fractures should affect 25% of the articular surface or greater.
• Fractures must have initial treatment within 72 hours of injury including initial injection of amobarbital or placebo.

Exclusion Criteria:

• Diabetes
• Pregnant or nursing mothers and individuals with child-bearing potential that are not using birth control methods with >99% efficacy.
• Allergy to poultry products or cinnamon
• Previous injuries to the ankle
• High grade open wounds
• Pre-existing immunologic or hematologic diseases
• Pre-existing ankle arthritis
• Ipsilateral fractures
• Associated injuries that preclude standard rehabilitation
• Pre-existing dysfunction of the kidneys, liver, blood, immune system, endocrine system (excluding diabetes)
• Serum creatinine >/= 1.4 mg/dl; BUN > 30 mg/dl; ALT >/= 60 IU/L in males and >/= 50 IU/L in females; AST >/= 45 IU/L in males and > 40 IU/L in females; bilirubin > 1.3 mg/dL; platelets </= 50,000/ul; glucose > 200 mg/dL

Related Conditions & MeSH terms

• Osteoarthritis
• Post-traumatic Osteoarthritis

Intervention

Drug:
• amobarbital/Gel-One (one dose)
One dose of amobarbital/Gel-One during the initial surgical intervention
• Placebo (single dose)
One dose of placebo during the initial surgical intervention
• amobarbital/Gel-One (two doses)
One dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
• Placebo (two doses)
One dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.

Locations

Country	Name	City	State
United States	University of Iowa	Iowa City	Iowa

Sponsors (2)

Lead Sponsor	Collaborator
J L Marsh	United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine the number of participants with systemic adverse events including the change in laboratory values to assess the systemic safety of amobarbital.	By using CBC and standard clinical chemistry assays to quantify circulating, ALT, AST, Bilirubin, Creatinine, and BUN and the measurement of urine protein content, the number of participants that have abnormal laboratory values will be determined.	Pre-op baseline on the day before external fixation surgery (within 24 hours of injury), immediately post-op, and at 1, 2, and 4 days post-op. At the time of internal fixation (3-21 days after external fixation) and at 1, 2, and 4 days post-op.]
Primary	Determine the number of participants with a change of local toxicity in tissues.	By using osteochondral fragments obtained during the internal fixation surgery, local toxicity will be determined by examining the tissue for cartilage and synovial histological changes.	Pre-op baseline on the day before external fixation surgery (within 24 hours of injury), immediately post-op, and at 1, 2, and 4 days post-op. At the time of internal fixation (3-21 days after external fixation) and at 1, 2, and 4 days post-op.
Secondary	Patient Reported Outcome Measurement Information Systems (PROMIS) - Pain Interference	Description: Pain interference 6 questions 5 pt scale - the higher the score the greater the pain	3, 6, 12, and 24 months
Secondary	Patient Reported Outcome Measurement Information Systems (PROMIS) Physical Function	Physical Function - T-score - mean of 50 and a standard deviation (SD) of 10. Therefore a person with a T-score of 40 is one SD below the mean. Higher is better.	Global Health - T-score - mean of 50 and a standard deviation (SD) of 10. Therefore a person with a T-score of 40 is one SD below the mean. Higher is better.
Secondary	Patient Reported Outcome Measurement Information Systems (PROMIS) Global Health questionnaires.	Global Health - T-score - mean of 50 and a standard deviation (SD) of 10. Therefore a person with a T-score of 40 is one SD below the mean. Higher is better.	3, 6, 12, and 24 months
Secondary	American Orthopaedic Foot and Ankle Society (AOFAS) Score.	0-100 point scale with 100 perfect ankle function	3, 6, 12, and 24 months
Secondary	Foot and Ankle Disability Index (FADI).	Description: total 104 points scored in a percentage scale with 100% perfect	3, 6, 12, and 24 months
Secondary	X-Ray based Kellgren-Lawrence Grade	Radiograph imaging graded on scale 1 (no arthritis)-4 (severe arthritis)	3, 6, 12, and 24 months
Secondary	CT-based fracture energy	Fracture energy is measured in Joules. It is from CT data and measured computationally. It is a continuous measure - Higher Joules = more energy = worse fracture	6 months
Secondary	CT-based Contact Stress	Vertical CT scan of ankle are segmented and analyzed using finite element analysis. Results are expressed as Contract Stress Exposure (MPa) across areas.	6 months
Secondary	CT-based Joint Space Width	Vertical CT scan of ankle used to measure Joint Space Width at several locations to measure distance to calculate the mean tibiotalar joint space (mm).	6 months